FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283756987> ?p ?o ?g. }

• W4283756987 endingPage "358" @default.
• W4283756987 startingPage "347" @default.
• W4283756987 abstract "Rapid joint clearance of small molecule drugs is the major limitation of current clinical approaches to osteoarthritis and its subtypes, including post-traumatic osteoarthritis (PTOA). Particulate systems such as nano/microtechnology could provide a potential avenue for improved joint retention of small molecule drugs. One drug of interest for PTOA treatment is flavopiridol, which inhibits cyclin-dependent kinase 9 (CDK9). Herein, polylactide-co-glycolide microparticles encapsulating flavopiridol were formulated, characterized, and evaluated as a strategy to mitigate PTOA-associated inflammation through the inhibition of CDK9. Characterization of the microparticles, including the drug loading, hydrodynamic diameter, stability, and release profile was performed. The mean hydrodynamic diameter of flavopiridol particles was ∼15 µm, indicating good syringeability and low potential for phagocytosis. The microparticles showed no cytotoxicity in-vitro, and drug activity was maintained after encapsulation, even after prolonged exposure to high temperatures (60 °C). Flavopiridol-loaded microparticles or blank (unloaded) microparticles were administered by intraarticular injection in a rat knee injury model of PTOA. We observed significant joint retention of flavopiridol microparticles compared to the soluble flavopiridol, confirming the sustained release behavior of the particles. Matrix metalloprotease (MMP) activity, an indicator of joint inflammation, was significantly reduced by flavopiridol microparticles 3 days post-injury. Histopathological analysis showed that flavopiridol microparticles reduced PTOA severity 28 days post-injury. Taken altogether, this work demonstrates a promising biomaterial platform for sustained small molecule drug delivery to the joint space as a therapeutic measure for post-traumatic osteoarthritis. Post-traumatic osteoarthritis (PTOA) begins with the deterioration of subchondral bone and cartilage after acute injuries. In spite of the prevalence of PTOA and its associated financial and psychological burdens, therapeutic measures remain elusive. A number of small molecule drugs are now under investigation to replace FDA-approved palliative measures, including cyclin-dependent kinase 9 (CDK9) inhibitors which work by targeting early inflammatory programming after injury. However, the short half-life of these drugs is a major hurdle to their success. Here, we show that biomaterial encapsulation of Flavopiridol (CDK9 inhibitor) in poly (lactic-co-glycolic acid) microparticles is a promising route for direct delivery and improved drug retention time in the knee joint. Moreover, administration of the flavopiridol microparticles reduced the severity of PTOA." @default.
• W4283756987 created "2022-07-02" @default.
• W4283756987 creator A5004256774 @default.
• W4283756987 creator A5004991727 @default.
• W4283756987 creator A5024109314 @default.
• W4283756987 creator A5032448354 @default.
• W4283756987 creator A5073670709 @default.
• W4283756987 creator A5089406747 @default.
• W4283756987 date "2022-09-01" @default.
• W4283756987 modified "2023-10-17" @default.
• W4283756987 title "Intra-articular injection of flavopiridol-loaded microparticles for treatment of post-traumatic osteoarthritis" @default.
• W4283756987 cites W1487479383 @default.
• W4283756987 cites W1539664785 @default.
• W4283756987 cites W1552097432 @default.
• W4283756987 cites W1793532565 @default.
• W4283756987 cites W1881648922 @default.
• W4283756987 cites W1886051612 @default.
• W4283756987 cites W1908291951 @default.
• W4283756987 cites W1968077631 @default.
• W4283756987 cites W1976906604 @default.
• W4283756987 cites W1980246074 @default.
• W4283756987 cites W1982167517 @default.
• W4283756987 cites W1984317348 @default.
• W4283756987 cites W1985569332 @default.
• W4283756987 cites W1993523958 @default.
• W4283756987 cites W2017712522 @default.
• W4283756987 cites W2018647053 @default.
• W4283756987 cites W2019598869 @default.
• W4283756987 cites W2020839425 @default.
• W4283756987 cites W2025505482 @default.
• W4283756987 cites W2038773696 @default.
• W4283756987 cites W2056282066 @default.
• W4283756987 cites W2072694036 @default.
• W4283756987 cites W2076104046 @default.
• W4283756987 cites W2076178719 @default.
• W4283756987 cites W2086444341 @default.
• W4283756987 cites W2087032263 @default.
• W4283756987 cites W2131042657 @default.
• W4283756987 cites W2148466312 @default.
• W4283756987 cites W2155677484 @default.
• W4283756987 cites W2167037356 @default.
• W4283756987 cites W2170117497 @default.
• W4283756987 cites W2346740611 @default.
• W4283756987 cites W2411356063 @default.
• W4283756987 cites W2427821467 @default.
• W4283756987 cites W2472154887 @default.
• W4283756987 cites W2513313441 @default.
• W4283756987 cites W2545035916 @default.
• W4283756987 cites W2776039151 @default.
• W4283756987 cites W2791239724 @default.
• W4283756987 cites W2806494694 @default.
• W4283756987 cites W2944753861 @default.
• W4283756987 cites W2965083651 @default.
• W4283756987 cites W2969810988 @default.
• W4283756987 cites W3127196935 @default.
• W4283756987 cites W3183835688 @default.
• W4283756987 doi "https://doi.org/10.1016/j.actbio.2022.06.042" @default.
• W4283756987 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35779774" @default.
• W4283756987 hasPublicationYear "2022" @default.
• W4283756987 type Work @default.
• W4283756987 citedByCount "7" @default.
• W4283756987 countsByYear W42837569872022 @default.
• W4283756987 countsByYear W42837569872023 @default.
• W4283756987 crossrefType "journal-article" @default.
• W4283756987 hasAuthorship W4283756987A5004256774 @default.
• W4283756987 hasAuthorship W4283756987A5004991727 @default.
• W4283756987 hasAuthorship W4283756987A5024109314 @default.
• W4283756987 hasAuthorship W4283756987A5032448354 @default.
• W4283756987 hasAuthorship W4283756987A5073670709 @default.
• W4283756987 hasAuthorship W4283756987A5089406747 @default.
• W4283756987 hasBestOaLocation W42837569872 @default.
• W4283756987 hasConcept C136229726 @default.
• W4283756987 hasConcept C142724271 @default.
• W4283756987 hasConcept C171250308 @default.
• W4283756987 hasConcept C192562407 @default.
• W4283756987 hasConcept C203014093 @default.
• W4283756987 hasConcept C204787440 @default.
• W4283756987 hasConcept C2776164576 @default.
• W4283756987 hasConcept C2776914184 @default.
• W4283756987 hasConcept C2779820397 @default.
• W4283756987 hasConcept C71924100 @default.
• W4283756987 hasConcept C98274493 @default.
• W4283756987 hasConceptScore W4283756987C136229726 @default.
• W4283756987 hasConceptScore W4283756987C142724271 @default.
• W4283756987 hasConceptScore W4283756987C171250308 @default.
• W4283756987 hasConceptScore W4283756987C192562407 @default.
• W4283756987 hasConceptScore W4283756987C203014093 @default.
• W4283756987 hasConceptScore W4283756987C204787440 @default.
• W4283756987 hasConceptScore W4283756987C2776164576 @default.
• W4283756987 hasConceptScore W4283756987C2776914184 @default.
• W4283756987 hasConceptScore W4283756987C2779820397 @default.
• W4283756987 hasConceptScore W4283756987C71924100 @default.
• W4283756987 hasConceptScore W4283756987C98274493 @default.
• W4283756987 hasFunder F4320306078 @default.
• W4283756987 hasFunder F4320332161 @default.
• W4283756987 hasFunder F4320338273 @default.
• W4283756987 hasLocation W42837569871 @default.
• W4283756987 hasLocation W42837569872 @default.

• next